1. The clinical features, treatment and prognosis of neutropenic fever and Coronavirus disease 2019 results of the multicentre teos study
- Author
-
Dilşah Başkol Elik, Şafak Kaya, Sevil Alkan, Tuna Demirdal, Alper Sener, Selçuk Kaya, Özlem Güzel Tunçcan, Bircan Kayaaslan, Rahmet Güner, Fatma Eser, Hasip Kahraman, Serhat Birengel, Elif Mukime Sarıcaoğlu, Esma Eroğlu, Fatma Çölkesen, Erman Öztürk, Hande Berk Cam, Çiğdem Mermutluoğlu, Şafak Özer Balin, Gülden Sincan, Nilgün Altın, Uluhan Sili, Bedia Mutay Suntur, Tuğba Arslan Gülen, Burak Deveci, Rabin Saba, Şaban İncecik, Gülden Eser Karlıdağ, Elif Hakko, Damla Akdağ, Hüseyin Aytaç Erdem, Hilal Sipahi, Candan Çicek, Mehmet Sezai Taşbakan, Meltem Taşbakan, Hüsnü Pullukçu, Tansu Yamazhan, Bilgin Arda, Sercan Ulusoy, and Oguz Resat Sipahi
- Subjects
Medicine ,Science - Abstract
Abstract This multicentre (22 centres in Turkey) retrospective cohort study aimed to assess the clinical outcomes of patients with neutropenic fever and SARS-CoV-2 positivity. Study period was 15 March 2020–15 August 2021. A total of 170 cases (58 female, aged 59 ± 15.5 years) that fulfilled the inclusion criteria were included in the study. One-month mortality rate (OMM) was 44.8%. The logistic regression analysis showed the following significant variables for the mentioned dependent variables: (i) achieving PCR negativity: receiving a maximum of 5 days of favipiravir (p = 0.005, OR 5.166, 95% CI 1.639–16.280); (ii) need for ICU: receiving glycopeptide therapy at any time during the COVID-19/FEN episode (p = 0.001, OR 6.566, 95% CI 2.137–20.172), the need for mechanical ventilation (p
- Published
- 2024
- Full Text
- View/download PDF